← back to search

James M. Murithi

Columbia University Irving Medical Center · US
Area of research
Public Health, Environmental and Occupational Health · Infectious Diseases
Research interest
Research interests include Malaria Research and Control, HIV/AIDS drug development and treatment, Mosquito-borne diseases and control, and Drug Transport and Resistance Mechanisms.
h-index
12
citations
916
works
20
NIH funding
primary concept
email

Recent publications

The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple <i>Plasmodium</i> kinases and life cycle stages
Science Translational Medicine 2022cited by 43position: middledoi
Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention
Cell chemical biology 2021cited by 80position: middledoi
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance
Science Translational Medicine 2021cited by 50position: firstdoi
The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957
Scientific Reports 2021cited by 12position: middledoi
Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial Activity
Cell chemical biology 2020cited by 90position: middledoi
Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery
Cell chemical biology 2019cited by 94position: firstdoi
Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents
PLoS Pathogens 2019cited by 82position: middledoi
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics
Science 2018cited by 273position: middledoi
Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity
Nature Microbiology 2017cited by 54position: middledoi
Dioxins and related environmental contaminants increase TDP-43 levels
Molecular Neurodegeneration 2017cited by 47position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David A. Fidock · Universidade Federal de Rondônia3 papers (2019–2021)Manu Vanaerschot · Columbia University2 papers (2019–2021)Elizabeth A. Winzeler · University of California San Diego2 papers (2019–2019)Sabine Ottilie · Scripps Research Institute1 papers (2019–2019) · 1 papers (2021–2021)Matthew Bogyo · Palo Alto University1 papers (2019–2019) · 1 papers (2021–2021)Euna Yoo · University of Kansas1 papers (2019–2019)Elizabeth A. Stanford · BC Children's Hospital1 papers (2017–2017)Jake Baum · UNSW Sydney1 papers (2021–2021) · 1 papers (2021–2021) · 1 papers (2021–2021)Susana Campino · London School of Hygiene & Tropical Medicine1 papers (2021–2021)da Fonseca · University of Glasgow1 papers (2019–2019)Manuel Llinás · Princeton University1 papers (2019–2019)Daniel E. Goldberg · University of Arizona1 papers (2019–2019)Matthew J. Fuchter · Imperial College Healthcare NHS Trust1 papers (2021–2021)Madeline R. Luth · University of California, San Diego1 papers (2019–2019)Kelly Chibale · University of Cape Town1 papers (2019–2019)Ali Al Abdulatif · Boston University1 papers (2017–2017)